Weekly Digest – April 2024 Weekly Digest – April 2024 26 Apr 2024: Breast cancer drug Enhertu’s breakthrough results unveiled at GBCC 2024 GBCC symposium reveals Enhertu’s breakthrough in HER2+ breast cancer: data presented highlights significant improvements in PFS and […]
Weekly Digest – April 2024 Weekly Digest – April 2024 17 Apr 2024: Bristol Myers Squibb finalizes a Global Strategic License and Collaboration Agreement with SystImmune for BL-B01D1, bolstering its position in the ADC arena Bristol Myers Squibb has completed […]
Weekly Digest – April 2024 Weekly Digest – April 2024 23 Apr 2024: Tharimmune Enters Option Agreement for Crucial Technologies in HER2/HER3 Antibody Drug Conjugates Tharimmune, Inc. secures an option agreement for an exclusive license with Washington University for the […]
Weekly Digest – April 2024 Weekly Digest – April 2024 22 Apr 2024: Salubris Biotherapeutics Secures $35 Million Investment and Unveils Pipeline Advancements Salubris Biotherapeutics, Inc. secured $35 million in new funding for ongoing research and development Clinical trial application […]
